ClinicalTrials.gg
Not yet recruitingNCT06974721Updated May 16, 2025

Wearable Flexible Sensors for Spinal Motion Monitoring

An observational study in Spine Disease, sponsored by Peking University Third Hospital. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Peking University Third Hospital · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
20
Ages
18 Years and older
Sex
All
01

Study summary

With the deepening of societal aging, degenerative spinal diseases have become increasingly prevalent in China and are one of the leading causes of disability among middle-aged and elderly populations. Current musculoskeletal assessment methods primarily focus on imaging rather than functional evaluation, and emphasize static over dynamic analysis, failing to capture the daily functional state of the musculoskeletal system. This limitation hinders a deeper understanding of functional patterns and their role in the progression of degenerative spinal diseases. Therefore, there is an urgent need to develop precise and dynamic functional assessment methods that overcome the constraints of time and space in measurement. This project adopts a dynamic perspective of the musculoskeletal system, developing a wearable monitoring approach based on flexible sensors to assess limb and spinal motion. The method will be validated against traditional imaging techniques such as X-ray and ultrasound, laying the foundation for investigating the pathogenesis of degenerative spinal diseases. This research aligns with China's strategic initiatives and practical needs in addressing the challenges of an aging population.

02

Conditions studied

  • Spine Disease

Browse trials for

Keywords

  • flexible sensor
  • spine disease
03

In context

Spinal Diseases

174 studies on the registry are indexed under Spinal Diseases; 39 are open to participants now.

This study's planned enrollment of 20 is below the median of 117 across 64 observational studies indexed under Spinal Diseases.

Browse Spinal Diseases studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 752 studies on the registry; 273 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

We are recruiting patients with spinal diseases, including cervical spondylosis with hand dysfunction, kyphosis/spinal imbalance, scoliosis (Cobb angle 20°-50°), and lumbar spondylolisthesis (>3mm dynamic slip).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of Spinal Cord Injury
  2. Clinical diagnosis of cervical spondylotic myelopathy with Impaired Hand Function
  3. Clinical diagnosis of Kyphosis
  4. Clinical diagnosis of Spinal Imbalance
  5. Clinical diagnosis of Scoliosis Patients
  6. Clinical diagnosis of Lumbar Spondylolisthesis Patients

Exclusion criteria

Exclusion Criteria:

  1. Obesity (>30)
  2. Inability to complete functional assessments due to physical condition or other reasons;
  3. Comorbid neuromuscular disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
20 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Motor and Stabilizing Function of the Spine

    The assessment of spinal stability at the baseline involves evaluating flexion-extension mobility in the sagittal plane, lateral bending capability in the coronal plane, and detecting relative displacement between vertebral segments during three-dimensional motion.

    Time frame: Baseline

Secondary outcomes

  1. Limb Motor Function

    Assessment of Limb Muscle Strength Function Using Dynamometer Grip Strength Tests and Hand Function Scoring at the baseline.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Wang Y, Zheng L, Yang J, Wang S. A Grip Strength Estimation Method Using a Novel Flexible Sensor under Different Wrist Angles. Sensors (Basel). 2022 Mar 4;22(5):2002. doi: 10.3390/s22052002. PubMed 35271152 ↗
  • Han G, Zhou S, Wang W, Li W, Qiu W, Li X, Fan X, Li W. Correlations between paraspinal extensor muscle endurance and clinical outcomes in preoperative LSS patients and clinical value of an endurance classification. J Orthop Translat. 2022 Sep 20;35:81-86. doi: 10.1016/j.jot.2022.08.005. eCollection 2022 Jul. PubMed 36196076 ↗
  • Li Z, Zhang S, Chen Y, Ling H, Zhao L, Luo G, Wang X, Hartel MC, Liu H, Xue Y, Haghniaz R, Lee K, Sun W, Kim H, Lee J, Zhao Y, Zhao Y, Emaminejad S, Ahadian S, Ashammakhi N, Dokmeci MR, Jiang Z, Khademhosseini A. Gelatin methacryloyl-based tactile sensors for medical wearables. Adv Funct Mater. 2020 Dec 1;30(49):2003601. doi: 10.1002/adfm.202003601. Epub 2020 Sep 6. PubMed 34366759 ↗
  • Hodges PW, Bailey JF, Fortin M, Battie MC. Paraspinal muscle imaging measurements for common spinal disorders: review and consensus-based recommendations from the ISSLS degenerative spinal phenotypes group. Eur Spine J. 2021 Dec;30(12):3428-3441. doi: 10.1007/s00586-021-06990-2. Epub 2021 Sep 20. PubMed 34542672 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Apr 2027, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 16, 2025
StartEst.
Jun 1, 2025
Primary completionEst.
Apr 1, 2027
CompletionEst.
Dec 1, 2027
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06974721
Collaborators
Xi'an Jiaotong University
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Jun 1, 2025 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
May 16, 2025

Study contacts

Weishi Li
Contact
hangengyu@pku.edu.cn
+8615701206146

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion